PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01154218
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TILACEMDrug: ANGIOTROFIN
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT01151345
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico, DF, Mexico
Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1002
- Registration Number
- NCT01151085
Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01149785
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee
Phase 2
Terminated
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 190
- Registration Number
- NCT01147458
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
Acute Response Capsaicin Flare Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01147432
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01147055
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Phase 4
Completed
- Conditions
- PsoriasisPsoriatic Arthritis
- Interventions
- Procedure: lab draws and imaging
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1013
- Registration Number
- NCT01147874
- Locations
- 🇨🇦
MAC Research Ind., Hamilton, Ontario, Canada
🇨🇦Lynderm Research Inc, Markham, Ontario, Canada
🇨🇦The Toronto Western Hospital-Division of Rheumatology, Toronto, Ontario, Canada
Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis
Phase 2
Terminated
- Conditions
- Chronic Pancreatitis
- Interventions
- Other: PlaceboBiological: Tanezumab
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT01146561
- Locations
- 🇺🇸
Carolinas Digestive Health Associates, Harrisburg, North Carolina, United States
🇺🇸Gastroenterology Group-of Naples, Naples, Florida, United States
🇺🇸Palm Beach Gastroenterology, Wellington, Florida, United States
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT01146327
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore